Title : Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.

Pub. Date : 2013 Oct

PMID : 24139422






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Patients with multiple sclerosis (MS) whose disease activity is inadequately controlled with a platform therapy (interferon beta or glatiramer acetate [GA]) may switch to another platform therapy or escalate therapy to natalizumab or fingolimod, which were approved in the US in 2006 and 2010, respectively. Fingolimod Hydrochloride interferon beta 1 Homo sapiens